Quantcast

Latest Treatments of Parkinson's Disease Stories

2009-03-04 07:00:00

Surveyed Neurologists and PCPs Vary in Their Prescribing Patterns of Levodopa/Carbidopa and Dopamine Agonists, According to a New Report from Decision Resources WALTHAM, Mass., March 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that second-line patient share of MAO-B inhibitors has increased from 14.1 percent to 35.2 percent since last year's report. Most of this increased patient share...

2009-02-16 08:11:00

LOS ANGELES, Feb. 16 /PRNewswire/ -- Scientists announced today the publication of a landmark peer-reviewed paper in the February issue of the Bentham Open Stem Cell Journal which outlines the long term results of the world's first clinical trial using autologous neural stem cells for the treatment of Parkinson's disease. According to lead author, Michel F. Levesque, MD, FRCS(C), FACS, "We have documented the first successful adult neural stem cell transplantation to reverse the effects...

2009-01-06 12:00:00

SEATTLE, Jan. 6 /PRNewswire/ -- Omeros Corporation today announced that The Michael J. Fox Foundation has awarded it a $465,000 grant against milestones to support the Company's collaboration with The Parkinson's Institute to evaluate Omeros' recent discovery of a new target for the treatment of Parkinson's disease. Located in regions of the brain responsible for Parkinson's disease, Omeros is the first to link its novel target to the treatment of any movement disorder, including Parkinson's...

2008-12-03 16:38:07

Levodopa has long been proven to provide the greatest relief of all available medications in the treatment of Parkinson's disease. It also is the most cost-effective drug for managing the full range of problems associated with this chronic neurological disorder, which affects an estimated one million Americans.In the Dec. 4 issue of the New England Journal of Medicine, Henry Ford Hospital neurologist Peter A. LeWitt, M.D., writes that levodopa should be used to not only treat both early and...

2008-11-06 09:00:45

Sun Pharmaceutical Industries, a specialty pharmaceutical company, has received the FDA approval for the company's abbreviated new drug application for generic Sinemet CR, an extended release version of carbidopa with levodopa. Carbidopa with levodopa extended release is indicated for the treatment of Parkinson's disease and syndrome. These generic extended release versions of carbidopa with levodopa are bio-equivalent to Sinemet CR marketed by Bristol-Myers and Squibb Company and will...

2008-11-05 12:00:30

DETROIT, Nov. 5 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. announced today, that it has launched Carbidopa and Levodopa tablets on behalf of Sun Pharmaceutical Industries Ltd. (Sun Pharma). Sun Pharma recently received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for generic Sinemet(R) tablets. Carbidopa and Levodopa tablets are used in the treatment of Parkinson's disease and syndrome. These generic...

2008-10-16 12:00:05

Neurogen's new dopamine agonist aplindore has shown positive results in Phase II trials in the treatment of Parkinson's disease and restless leg syndrome. Datamonitor estimates dopamine agonist sales in these indications were worth $1.5 billion in 2007. However, aplindore's clinical profile suggests that it could be more competitive in the restless leg syndrome than the Parkinson's disease market. Neurogen has announced positive Phase II results for its investigational drug aplindore, in...

2008-09-19 09:00:41

Omeros and The Parkinson's Institute and Clinical Center have entered into a collaboration to evaluate a novel target, proprietary to Omeros, for the treatment of movement disorders. Under the collaboration, Omeros and The Parkinson's Institute will conduct laboratory studies of one or more compounds that block Omeros's proprietary target in a widely used and highly predictive model for the symptomatic treatment of Parkinson's disease. The collaboration is based on Omeros's discovery and...

2008-09-18 03:00:24

AMSTERDAM, The Netherlands, September 18 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that it obtained a license from Amgen to use their GDNF gene for the development of a gene therapy treatment for Parkinson's disease. The combination of this gene with AMT's proprietary adeno-associated virus (AAV) gene therapy platform could potentially allow the development of an effective, long-term treatment for...

2008-09-17 09:01:00

SEATTLE and SUNNYVALE, Calif., Sept. 17 /PRNewswire/ -- Omeros Corporation and The Parkinson's Institute and Clinical Center today announced that they have entered into a collaboration to evaluate a novel target, proprietary to Omeros, for the treatment of movement disorders. The collaboration is based on Omeros' discovery and prior validation of a previously unknown link between this molecular target in the brain and movement disorders such as Parkinson's disease and Restless Legs Syndrome...


Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related